… קידום אתרים – חימום ביתי עם קמין זה דבר הרבה יותר מאשר נהג שנשכר לצורך משימה ספציפית. אז ברור כי במידה ויש צניחה בדרוג, צניחה שאינה מוסברת בצורה אחרת. ** מכיוון שרוב חיפושי העולם מתבצעים בגוג… Best in Aid: The Grand Prize ……

I am without a doubt on your side of the AID debate, but there are elements of aggression in your approach which can put off those who want to agree with you.

I see, understood. I am not much aware of the aidwatch blog drama that goes on, sorry

When analysts do their initial scan of organisations seeking funding they will first check the web site and assess three things:
1) transparency
2) efficiency
3) effectiveness

Transparency – who are you, where and how are you registered, what is your governance structure and what are the individual biographies of the senior executives and board of directors.
Efficiency – are there available to download several years (5 is good) of audited financial statements (not synoposes) including the auditor’s notes and signed comment.
Effectiveness – are there independent third party evaluations of the organisation’s programme effectiveness. In other words no anecdotal cherry-picking.

The last factor is a trend being driven by an honest desire by organisations to demonstrate that they do effective work and to put some distance between themselves and those groups that do not.

When working in India, I helped prepare for my client a set of bylaws which included a provision that the membership at the annual meeting appoint, in the same manner as they would an auditor, an independent evaluator who would then report to the membership how effective their organisation is.

This is a work in progress, but over time, I would expect to see a professional body of evaluators being formed with the same level of skill and accountability as we see with accountants.

That is an odd stance. Would you oppose the creation of the US Food and Drug Administration, which evaluates pharmaceuticals based on randomized trials, until a meta-trial had been completed comparing patient outcomes under drugs that had been rigorously evaluated by the FDA to patient outcomes under un-evaluated pharaceuticals?

A good first step is to do *any* rigorous evaluation at all, as Aidwatch suggests. Such evaluation remains mostly absent from the worldwide aid industry.